COMP <GO>
HSIC vs ABBV // 10Y YIELD & FRED MACRO BETA
Henry Schein Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HSIC 3
— ABBV 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $84.88 (-1.80%) • MKT CAP: $9.63B
macro-sensitivity
0.89
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HSIC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HSIC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.10% | 70.20% | -39.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.20% | 29.00% | -17.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.5x | 33.3x | -23.80 | HSIC | /valuation <GO> |
| Free Cash Flow Yield | 1.23% | 3.47% | -2.24 | ABBV | /fcf-yield <GO> |
| Operating Margin | 5.00% | 24.60% | -19.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.20% | 6.90% | -3.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.00% | 8.60% | -4.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 5.33 | -2.52 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.40% | -0.90 | HSIC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 72.8 | -24.98 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.89 | 1.15 | -0.26 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.4x | 113.1x | -91.70 | HSIC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.63B | $513.86B | -$504.23B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HSIC REV | ABBV REV | HSIC GROSS % | ABBV GROSS % | HSIC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.18B | $61.16B | 31.1% | 70.2% | $118.7M | $17.82B |
| FY 2024 | $12.67B | $56.33B | 31.7% | 70.0% | $277.7M | $17.83B |
| FY 2023 | $12.34B | $54.32B | 44.0% | 44.0% | -$55.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HSIC // BETA 0.89
ABBV // BETA 1.15